Receive The Newest Study Notifications

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce plans to initiate in 2019 a clinical trial of Brilacidin, its novel defensin-mimetic drug candidate, as an oral dosage form. Building upon the...

Study Abstract Presented at the 2019 APSARD Annual Meeting in Washington, DC VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and leader in developing specialty nutrition, announced today recently completed brain imaging study results utilizing functional...

Shared platform with pharmaceutical firms streamlines, cuts costs in hospital operations Fujitsu has enhanced its clinical trial-supporting Fujitsu Life Science Solution tsClinical DDworks21 series with the launch of the SaaS solution tsClinical DDworks21/Trial Site....

Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a clinical trial of its proprietary, next generation prostate cancer drug, VERU-111. The open-label Phase 1b/2 clinical...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO) inhibitor, which...

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically...

- ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development - Phase I dose escalation and expansion trial will evaluate ADCT-601 in 75 cancer patients - ADCT-601 is BerGenBio's third...

The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company, today announced that a human stem cell-derived product candidate has been...

 ImaginAb, Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb's CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases has announced its plans to initiate a Phase III trial to evaluate the efficacy of its lead drug, NB-01, in diabetic...

"It is with great satisfaction we can announce acceptance from the FDA and the Central Ethics Committee to initiate the Xplore trial. Applications to the additional countries are being submitted continuously during January and February. First patient in is expected...

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors Lausanne, Switzerland, January 16, 2019 - ADC Therapeutics, an oncology drug discovery and development company that specializes in the...

Sernova Corp. (SVA) (otcqb:SEOVF), a clinical-stage regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase I/II trial of Sernova's Cell Pouch(TM) for Clinical Islet Transplantation in type 1 diabetes. "We are...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate...

ONEVoice, a landmark survey funded by the Muscular Dystrophy Association (MDA) and conducted by Edge Research, has identified key areas of concern among more than 3,000 respondents – 2,430 adults with neuromuscular disease and 932 caregivers/family members – as well...

Flower Orthopedics is pleased to announce the results of a 14-month, multi-center, prospective trial comparing the use of the FlowerCube system to traditional implants in first metatarsal phalangeal joint fusions in 71 consecutive patients. This study, led by Dr. John...

- AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. - The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. - Secondary imaging endpoints will include measures of...

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically...

-PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced PharmaCyte’s partner, Austrianova, has...

Can krill oil improve the quality of life of people living with systemic lupus erythematous? A clinical trial, involving 20 centers in the United States, is currently enrolling patients to answer this question. Hospital for Special Surgery (HSS), in New York City, is...